 Drug Synergism
"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.812.240.477 G07.700.680.240.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 1 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 0 | 2 | 2 | | 1985 | 0 | 2 | 2 | | 1986 | 0 | 3 | 3 | | 1987 | 0 | 5 | 5 | | 1988 | 0 | 8 | 8 | | 1989 | 0 | 3 | 3 | | 1990 | 0 | 3 | 3 | | 1991 | 0 | 2 | 2 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 6 | 6 | | 1994 | 0 | 4 | 4 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 5 | 5 | | 1998 | 0 | 9 | 9 | | 1999 | 0 | 5 | 5 | | 2000 | 0 | 5 | 5 | | 2001 | 0 | 8 | 8 | | 2002 | 0 | 11 | 11 | | 2003 | 0 | 6 | 6 | | 2004 | 0 | 8 | 8 | | 2005 | 1 | 6 | 7 | | 2006 | 0 | 7 | 7 | | 2007 | 0 | 5 | 5 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 5 | 5 | | 2011 | 0 | 8 | 8 | | 2012 | 1 | 7 | 8 | | 2013 | 1 | 8 | 9 | | 2014 | 0 | 6 | 6 | | 2015 | 0 | 11 | 11 | | 2016 | 0 | 8 | 8 | | 2017 | 1 | 8 | 9 | | 2018 | 0 | 7 | 7 | | 2019 | 0 | 3 | 3 | | 2020 | 0 | 3 | 3 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Khomtchouk KM, Joseph LI, Khomtchouk BB, Kouhi A, Massa S, Xia A, Koliesnik I, Pletzer D, Bollyky PL, Santa Maria PL. Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media. NPJ Biofilms Microbiomes. 2021 04 06; 7(1):31.
-
Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.
-
Nazari F, Oklejas AE, Nör JE, Pearson AT, Jackson TL. In Silico Models Accurately Predict In Vivo Response for IL6 Blockade in Head and Neck Cancer. Cancer Res. 2020 04 01; 80(7):1451-1460.
-
Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, Caporaso JG, Crandall KA, Simone NL, Godoy-Vitorino F, Griffin TJ, Whiteson KL, Gustafson HH, Slade DJ, Schmidt TM, Walther-Antonio MRS, Korem T, Webb-Robertson BM, Styczynski MP, Johnson WE, Jobin C, Ridlon JM, Koh AY, Yu M, Kelly L, Wargo JA. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer. 2020 03; 6(3):192-204.
-
Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W, Korman AJ, Coussens LM, Swartz MA, Hanahan D. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. Cancer Immunol Res. 2020 01; 8(1):131-145.
-
Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJ. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.
-
El Bissati K, Redel H, Ting LM, Lykins JD, McPhillie MJ, Upadhya R, Woster PM, Yarlett N, Kim K, Weiss LM. Novel Synthetic Polyamines Have Potent Antimalarial Activities in vitro and in vivo by Decreasing Intracellular Spermidine and Spermine Concentrations. Front Cell Infect Microbiol. 2019; 9:9.
-
Wang X, Wu X, Zhang Z, Ma C, Wu T, Tang S, Zeng Z, Huang S, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Shen Y, Luo W, Wang X, Liu B, Lei Y, Ye Z, Zhao L, Cao D, Yang L, Chen X, Haydon RC, Luu HH, Peng B, Liu X, He TC. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep. 2018 12 17; 8(1):17914.
-
Wang J, Shao L, Wang CZ, Zhou HH, Yuan CS, Huang WH. Synergetic Inhibition of Human Colorectal Cancer Cells by Combining Polyyne-Enriched Fraction from Oplopanax elatus and Irinotecan. Nutr Cancer. 2019; 71(3):472-482.
-
Goss CH, Kaneko Y, Khuu L, Anderson GD, Ravishankar S, Aitken ML, Lechtzin N, Zhou G, Czyz DM, McLean K, Olakanmi O, Shuman HA, Teresi M, Wilhelm E, Caldwell E, Salipante SJ, Hornick DB, Siehnel RJ, Becker L, Britigan BE, Singh PK. Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. Sci Transl Med. 2018 09 26; 10(460).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|